NCT01918709View on ClinicalTrials.gov

Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Hypertension, Hyperlipidemia

Interventions

DRUG

Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)

Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

DRUG

Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)

Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

DRUG

Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)

Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

DRUG

Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)

Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

DRUG

Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)

Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

DRUG

Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)

Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug

Trial Locations (1)

Unknown

Clinical Trial Center, Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

LG Life Sciences

All Listed Sponsors

lead

LG Life Sciences

INDUSTRY